Cochrane · systematic review · CD010927
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
Zani, B, Gathu, M, Donegan, S, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Africa
Population: Patients with uncomplicated P. falciparum malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure Day 28 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine | RR 0.34 [0.3, 0.39] | 9 studies · 6200 participants | High |
Treatment failure Day 63 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine | RR 0.71 [0.65, 0.78] | 2 studies · 3200 participants | High |